Skip to main content
SpringerLink
Log in

Erlotinib improves QOL in Chinese patients with NSCLC

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. epidermal growth factor receptor

  2. The phase III, open-label study, conducted at 22 sites in China, compared the efficacy and safety of first-line erlotinib with gemcitabine-carboplatin in Chinese patients with locally advanced or metastatic EGFR mutation-positive NSCLC. The study was supported by partial research grants from F. Hoffmann-La Roche (China).

Reference

  • Chen G, et al. Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). Annals of Oncology : Mar 2013. Available from: URL: http://dx.doi.org/10.1093/annonc/mdt012

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Erlotinib improves QOL in Chinese patients with NSCLC. PharmacoEcon Outcomes News 674, 9 (2013). https://doi.org/10.1007/s40274-013-0253-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-013-0253-5

Search

Navigation